1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Dystrophic Epidermolysis Bullosa - Introduction
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
4.3 Market Overview (2018-2023) and Forecast (2024-2034)
4.4 Competitive Intelligence
5 Dystrophic Epidermolysis Bullosa - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Dystrophic Epidermolysis Bullosa - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
8 Dystrophic Epidermolysis Bullosa - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Dystrophic Epidermolysis Bullosa Guidelines, Management and Treatment
8.2 Dystrophic Epidermolysis Bullosa Treatment Algorithm
9 Dystrophic Epidermolysis Bullosa - Unmet Needs
10 Dystrophic Epidermolysis Bullosa - Key Endpoints of Treatment
11 Dystrophic Epidermolysis Bullosa - Marketed Products
11.1 List of Dystrophic Epidermolysis Bullosa Marketed Drugs Across the Top 7 Markets
11.1.1 Filsuvez (Birch triterpenes) - Amryt Pharma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
12 Dystrophic Epidermolysis Bullosa - Pipeline Drugs
12.1 List of Dystrophic Epidermolysis Bullosa Pipeline Drugs Across the Top 7 Markets
12.1.1 Dabocemagene autoficel - Fibrocell Science
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Beremagene geperpavec - Krystal Biotech
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 EB-101 - Abeona Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 PTR-01 - Phoenix Tissue Repair
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Timbetasin - RegeneRx Biopharmaceuticals
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report
13 Dystrophic Epidermolysis Bullosa - Attribute Analysis of Key Marketed and Pipeline Drugs
14 Dystrophic Epidermolysis Bullosa - Market Scenario
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Dystrophic Epidermolysis Bullosa - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034)
14.2.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034)
14.3 Market Scenario - United States
14.3.1 Dystrophic Epidermolysis Bullosa - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034)
14.3.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034)
14.3.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Dystrophic Epidermolysis Bullosa - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034)
14.4.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034)
14.4.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Dystrophic Epidermolysis Bullosa - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034)
14.5.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034)
14.5.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Dystrophic Epidermolysis Bullosa - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034)
14.6.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034)
14.6.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Dystrophic Epidermolysis Bullosa - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034)
14.7.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034)
14.7.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Dystrophic Epidermolysis Bullosa - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034)
14.8.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034)
14.8.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Dystrophic Epidermolysis Bullosa - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034)
14.9.2 Dystrophic Epidermolysis Bullosa - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034)
14.9.3 Dystrophic Epidermolysis Bullosa - Access and Reimbursement Overview
15 Dystrophic Epidermolysis Bullosa - Recent Events and Inputs From Key Opinion Leaders
16 Dystrophic Epidermolysis Bullosa Market - SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 Appendix